An Executive Informational Overview (EIO) is now available on specialty pharmaceutical company, Hemispherx Biopharma, Inc. (HEB-NYSE). The EIO is a 60-page report detailing Hemispherx's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

An Executive Informational Overview (EIO) is now available on a revenue-generating Canadian biotechnology company, Ceapro Inc. (CZO-TSX.V). The EIO is a 64-page report detailing Ceapro's business, products and pipeline, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

An Executive Informational Overview (EIO) is now available on an alternative energy company, MagneGas Corp. (MNGA-NASDAQ). The EIO is a 68-page report detailing MagneGas' business strategy, products, market opportunities, competition, financials, risks, and more. It is available for download below.

Crystal Research Associates has released a 16-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial and regulatory filing milestones, and financial position. 

• Up to 80% of colorectal biopsies performed are subsequently identified as normal, non-cancerous tissue. Incorporating an optical biopsy, such as WavSTAT4, before performing an invasive physical biopsy reduces risks to patients by eliminating many unnecessary procedures and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.

• SpectraScience is working to diagnose “pre-cancers”—suspect tissue or areas in the body before it becomes cancerous. Tissue that WavSTAT4 finds to be precancerous (or cancerous) returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.

• Major 2016 corporate developments include a strategic acquisition, research publication, and development of an international sales infrastructure enabling the start of device sales in the Middle East.

Crystal Research Associates has recently released Executive Informational Overview (EIO) reports on both Ra Medical Systems, Inc., a profitable medical device company commercializing a new laser system for vascular diseases, and Biosceptre International Ltd., a development-stage immune-oncology company that has identified a new molecular target for cancer treatments.

We have just published a new set of slides that summarize the key elements of each of these companies, from business and product overviews to market sizes and growth strategies.

An Executive Informational Overview (EIO) is now available on a closely held medical device company, Ra Medical Systems, Inc. The EIO is a 56-page report detailing Ra Medical's business strategy, products, market opportunities, competition, financials, risks, and more. It is available for download below.

An Executive Informational Overview (EIO) is now available on a closely held, UK-based, biotech research and development company called Biosceptre International Ltd. The EIO released Tuesday is a 52-page report detailing Biosceptre's business, novel technology and product development, market opportunities, competition, financials, risks, and more. It is available for download below.

This month, Small Cap Nation's Jane King sat down with Crystal Research Associates' CEO Jeffrey Kraws to discuss the current state and future outlook of our research company. The interview, available below, also included a discussion of important trends facing the corporate research and communications industry as well as factors impacting some of the industries we serve (e.g., healthcare).

Tomorrow kicks off one of the year’s largest oncology conferences: the American Society of Clinical Oncology (ASCO) Annual Meeting, held this year over June 3-7 at McCormick Place in Chicago. With over 30,000 attendees and hundreds of presenting companies, the conference will undoubtedly include important clinical data announcements from the likes of Pfizer, Genentech, and others as well as give some smaller firms the opportunity to introduce novel oncology candidates. Amid the presentations and exhibitions, one topic in particular is expected to stand out: the costs of cancer care.

This week, Catasys, Inc. (CATS-OTC) reported its financial results for the first quarter 2016, ended March 31, 2016. Catasys provides Big Data–based analytics and predictive modeling–driven behavioral healthcare services to health plans and their members through its 52-week, outpatient OnTrak programs. The company reports that patient enrollment in its programs has increased by more than 175% since the beginning of 2015.

Specialty biopharmaceutical company Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX) held a conference call and webcast this morning to discuss its first quarter 2016 financial and operating results. A link to a replay of the full webcast is available here.

Over the past several decades, there has been a change in how the U.S. views mental health issues. Today, a conversation about a tragic shooting has transitioned from being an “NRA issue” to a “mental health issue,” with these topics being picked up by industry, media, and politicians alike. With near-daily news reports of teenage or young adult suicides, attacks on family, military, schools, movie theaters, and so on by undiagnosed and untreated individuals, and a rise in accidental drug overdoses from both illicit and prescription products, today's conversations have begun to focus on increasing fairness in health insurance for behavioral and mental health conditions while reducing the stigma, costs, and hopelessness of seeking treatment for those who are suffering from a mental or substance use disorder.

Crystal Research Associates has released a 16-page Quarterly Update on specialty biopharmaceutical company, Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). The Update specifically details Aeterna's recent news and developments, recent and anticipated clinical trial milestones, and financial position. 

Showroom Now Open in Shanghai

Saleen Automotive Inc. (SLNN-OTC) reported today that the Saleen brand opened its first international showroom in Shanghai, China. The elegant showroom is located in the upscale Jing An District in Shanghai and will not only assist in broadening the Saleen experience but also furthering the brand.